Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Repurposing Cilostazol for Raynaud's Phenomenon

Author(s): Nehme El-Hachem, Manal M. Fardoun, Hasan Slika, Elias Baydoun and Ali H. Eid*

Volume 28, Issue 12, 2021

Published on: 03 September, 2020

Page: [2409 - 2417] Pages: 9

DOI: 10.2174/0929867327666200903114154

Price: $65

conference banner
Abstract

Raynaud's Phenomenon (RP) results from exaggerated cold-induced vasoconstriction. RP patients suffer from vasospastic attacks and compromised digital blood perfusion leading to a triple color change at the level the fingers. Severe RP may cause ulcers and threaten tissue viability. Many drugs have been used to alleviate the symptoms of RP. These include calcium-channel blockers, cGMP-specific phosphodiesterase type 5 inhibitors, prostacyclin analogs, and angiotensin receptor blockers. Despite their variety, these drugs do not treat RP but rather alleviate its symptoms. To date, no drug for RP has been yet approved by the U.S Food and Drugs Administration. Cilostazol is a selective inhibitor of phosphodiesterase-III, originally prescribed to treat intermittent claudication. Owing to its antiplatelet and vasodilating properties, cilostazol is being repurposed as a potential drug for RP. This review focuses on the different lines of action of cilostazol serving to enhance blood perfusion in RP patients.

Keywords: Cardiovascular disease, cilostazol, digital ischemia, drug repurposing, Raynaud's phenomenon, Cold-induced vasoconstriction.

« Previous Next »
[1]
Vane, J.R. The fight against rheumatism: from willow bark to COX-1 sparing drugs. J. Physiol. Pharmacol., 2000, 51(4 Pt 1), 573-586.
[PMID: 11192932]
[2]
Desborough, M.J.R.; Keeling, D.M. The aspirin story - from willow to wonder drug. Br. J. Haematol., 2017, 177(5), 674-683.
[http://dx.doi.org/10.1111/bjh.14520] [PMID: 28106908]
[3]
Flemming, A. Cancer: Of targets and anti-targets. Nat. Rev. Drug Discov., 2012, 11(7), 515.
[http://dx.doi.org/10.1038/nrd3781] [PMID: 22722534]
[4]
Jourdan, J.P.; Bureau, R.; Rochais, C.; Dallemagne, P. Drug repositioning: a brief overview. J. Pharm. Pharmacol., 2020.
[http://dx.doi.org/10.1111/jphp.13273] [PMID: 32301512]
[5]
Holstein, S.A.; McCarthy, P.L. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs, 2017, 77(5), 505-520.
[http://dx.doi.org/10.1007/s40265-017-0689-1] [PMID: 28205024]
[6]
Kale, V.P.; Habib, H.; Chitren, R.; Patel, M.; Pramanik, K.C.; Jonnalagadda, S.C.; Challagundla, K.; Pandey, M.K. Old drugs, new uses: drug repurposing in hematological malignancies. Semin. Cancer Biol., 2020, 68, 242-248.
[http://dx.doi.org/10.1016/j.semcancer.2020.03.005] [PMID: 32151704]
[7]
Goldstein, I.; Burnett, A.L.; Rosen, R.C.; Park, P.W.; Stecher, V.J. The serendipitous story of sildenafil: an unexpected oral therapy for erectile dysfunction. Sex. Med. Rev., 2019, 7(1), 115-128.
[http://dx.doi.org/10.1016/j.sxmr.2018.06.005] [PMID: 30301707]
[8]
Kass, D.A.; Champion, H.C.; Beavo, J.A. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ. Res., 2007, 101(11), 1084-1095.
[http://dx.doi.org/10.1161/CIRCRESAHA.107.162511] [PMID: 18040025]
[9]
Gelosa, P.; Castiglioni, L.; Camera, M.; Sironi, L. Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream? Biochem. Pharmacol., 2020, 177, 113894.
[http://dx.doi.org/10.1016/j.bcp.2020.113894] [PMID: 32142728]
[10]
Dudley, J.; Berliocchi, L. Drug repositioning: approaches and applications for neurotherapeutics; CRC press: Boca Raton, 2017, Vol. 1, .
[http://dx.doi.org/10.4324/9781315373669]
[11]
Landry, G.J. Current medical and surgical management of Raynaud’s syndrome. J. Vasc. Surg., 2013, 57(6), 1710-1716.
[http://dx.doi.org/10.1016/j.jvs.2013.03.012] [PMID: 23618525]
[12]
Herrick, A.L. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat. Rev. Rheumatol., 2012, 8(8), 469-479.
[http://dx.doi.org/10.1038/nrrheum.2012.96] [PMID: 22782008]
[13]
Pauling, J.D.; Hughes, M.; Pope, J.E. Raynaud’s phenomenon-an update on diagnosis, classification and management. Clin. Rheumatol., 2019, 38(12), 3317-3330.
[http://dx.doi.org/10.1007/s10067-019-04745-5] [PMID: 31420815]
[14]
Block, J.A.; Sequeira, W. Raynaud’s phenomenon. Lancet, 2001, 357(9273), 2042-2048.
[http://dx.doi.org/10.1016/S0140-6736(00)05118-7] [PMID: 11438158]
[15]
Prete, M.; Fatone, M.C.; Favoino, E.; Perosa, F. Raynaud’s phenomenon: from molecular pathogenesis to therapy. Autoimmun. Rev., 2014, 13(6), 655-667.
[http://dx.doi.org/10.1016/j.autrev.2013.12.001] [PMID: 24418302]
[16]
Fardoun, M.M.; Nassif, J.; Issa, K.; Baydoun, E.; Eid, A.H. Raynaud’s phenomenon: a brief review of the underlying mechanisms. Front. Pharmacol., 2016, 7, 438.
[http://dx.doi.org/10.3389/fphar.2016.00438] [PMID: 27899893]
[17]
Lis-Święty, A. Recent advances in the workup and management of Raynaud phenomenon Pol. Arch. Intern. Med., 2019, 129(11), 798-808.
[http://dx.doi.org/10.20452/pamw.15008] [PMID: 31577265]
[18]
Bakst, R.; Merola, J.F.; Franks, A.G., Jr; Sanchez, M. Raynaud’s phenomenon: pathogenesis and management. J. Am. Acad. Dermatol., 2008, 59(4), 633-653.
[http://dx.doi.org/10.1016/j.jaad.2008.06.004] [PMID: 18656283]
[19]
Sama, C-B. Post-traumatic dgital gangrene associated with epinephrine use in primary Raynaud’s phenomenon: lesson for the future. Ethiop. J. Health Sci., 2016, 26(4), 401-404.
[http://dx.doi.org/10.4314/ejhs.v26i4.13] [PMID: 27587939]
[20]
Charkoudian, N. Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans. J. Appl. Physiol., 2010, 109(4), 1221-1228.
[http://dx.doi.org/10.1152/japplphysiol.00298.2010] [PMID: 20448028]
[21]
Wigley, F.M.; Flavahan, N.A. Raynaud’s Phenomenon. N. Engl. J. Med., 2016, 375(6), 556-565.
[http://dx.doi.org/10.1056/NEJMra1507638] [PMID: 27509103]
[22]
Chotani, M.A.; Flavahan, S.; Mitra, S.; Daunt, D.; Flavahan, N.A. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am. J. Physiol. Heart Circ. Physiol., 2000, 278(4), H1075-H1083.
[http://dx.doi.org/10.1152/ajpheart.2000.278.4.H1075] [PMID: 10749700]
[23]
MacDonald, E.; Kobilka, B.K.; Scheinin, M. Gene targeting--homing in on α 2-adrenoceptor-subtype function. Trends Pharmacol. Sci., 1997, 18(6), 211-219.
[http://dx.doi.org/10.1016/S0165-6147(97)01063-8] [PMID: 9227000]
[24]
von Zastrow, M.; Kobilka, B.K. Antagonist-dependent and -independent steps in the mechanism of adrenergic receptor internalization. J. Biol. Chem., 1994, 269(28), 18448-18452.
[PMID: 7518433 ]
[25]
Bailey, S.R.; Eid, A.H.; Mitra, S.; Flavahan, S.; Flavahan, N.A. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of α2C-adrenoceptor translocation. Circ. Res., 2004, 94(10), 1367-1374.
[http://dx.doi.org/10.1161/01.RES.0000128407.45014.58] [PMID: 15087420]
[26]
Jeyaraj, S.C.; Chotani, M.A.; Mitra, S.; Gregg, H.E.; Flavahan, N.A.; Morrison, K.J. Cooling evokes redistribution of α2C-adrenoceptors from golgi to plasma membrane in transfected human embryonic kidney 293 cells. Mol. Pharmacol., 2001, 60(6), 1195-1200.
[http://dx.doi.org/10.1124/mol.60.6.1195] [PMID: 11723226]
[27]
Jeyaraj, S.C.; Unger, N.T.; Eid, A.H.; Mitra, S.; Paul El-Dahdah, N.; Quilliam, L.A.; Flavahan, N.A.; Chotani, M.A. Cyclic AMP-Rap1A signaling activates RhoA to induce α(2c)-adrenoceptor translocation to the cell surface of microvascular smooth muscle cells. Am. J. Physiol. Cell Physiol., 2012, 303(5), C499-C511.
[http://dx.doi.org/10.1152/ajpcell.00461.2011] [PMID: 22621783]
[28]
Eid, A.H.; Chotani, M.A.; Mitra, S.; Miller, T.J.; Flavahan, N.A. Cyclic AMP acts through Rap1 and JNK signaling to increase expression of cutaneous smooth muscle alpha(2C)-adrenoceptors. Am. J. Physiol. Heart Circ. Physiol., 2008, 295(1), H266-H272.
[http://dx.doi.org/10.1152/ajpheart.00084.2008] [PMID: 18487435]
[29]
Halawa, B. Calcium channel blockers in the treatment of cardiovascular disease. Pol. Merkur. Lekarski., 2001, 11(61), 83-87.
[PMID: 11579840]
[30]
Sturgill, M.G.; Seibold, J.R. Rational use of calcium-channel antagonists in Raynaud’s phenomenon. Curr. Opin. Rheumatol., 1998, 10(6), 584-588.
[http://dx.doi.org/10.1097/00002281-199811000-00013] [PMID: 9812220]
[31]
Rirash, F.; Tingey, P.C.; Harding, S.E.; Maxwell, L.J.; Tanjong Ghogomu, E.; Wells, G.A.; Tugwell, P.; Pope, J. Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst. Rev., 2017. 12CD000467.
[http://dx.doi.org/10.1002/14651858.CD000467.pub2] [PMID: 29237099]
[32]
Ennis, H.; Hughes, M.; Anderson, M.E.; Wilkinson, J.; Herrick, A.L. Calcium channel blockers for primary Raynaud’s phenomenon. Cochrane Database Syst. Rev., 2016. 2CD002069.
[http://dx.doi.org/10.1002/14651858.CD002069.pub5] [PMID: 26914257]
[33]
Negrini, S.; Magnani, O.; Matucci-Cerinic, M.; Carignola, R.; Data, V.; Montabone, E.; Santaniello, A.; Adorni, G.; Murdaca, G.; Puppo, F.; Indiveri, F.; Della Rossa, A.; D’Ascanio, A.; Barsotti, S.; Giuggioli, D.; Ferri, C.; Lumetti, F.; Bosello, S.L.; Canestrari, G.; Bellando Randone, S.; Bruni, C.; Guiducci, S.; Battaglia, E.; De Andres, M.I.; Russo, A.A.; Beretta, L. Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. Clin. Exp. Med., 2019, 19(3), 357-366.
[http://dx.doi.org/10.1007/s10238-019-00553-y] [PMID: 30989453]
[34]
Lee, E.Y.; Park, J.K.; Lee, W.; Kim, Y.K.; Park, C.S.; Giles, J.T.; Park, J.W.; Shin, K.; Lee, J.S.; Song, Y.W.; Lee, E.B. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud’s phenomenon: a double-blind, randomized, cross-over study. Rheumatology (Oxford), 2014, 53(4), 658-664.
[http://dx.doi.org/10.1093/rheumatology/ket417] [PMID: 24352340]
[35]
Temprano, K.K. A review of raynaud’s disease. Mo. Med., 2016, 113(2), 123-126.
[PMID: 27311222]
[36]
Regulski, M.; Regulska, K.; Stanisz, B.J.; Murias, M.; Gieremek, P.; Wzgarda, A.; Niznik, B. Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Curr. Pharm. Des., 2015, 21(13), 1764-1775.
[http://dx.doi.org/10.2174/1381612820666141112160013] [PMID: 25388457]
[37]
Linnemann, B.; Erbe, M. Raynaud’s phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options. Vasa, 2016, 45(3), 201-212.
[http://dx.doi.org/10.1024/0301-1526/a000526] [PMID: 27129065]
[38]
Agustí, A.; Bonet, S.; Arnau, J.M.; Vidal, X.; Laporte, J.R. Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction: meta-analysis of randomised clinical trials. Drug Saf., 2003, 26(12), 895-908.
[http://dx.doi.org/10.2165/00002018-200326120-00004] [PMID: 12959631]
[39]
Wigley, F.M. Clinical practice. Raynaud’s phenomenon. N. Engl. J. Med., 2002, 347(13), 1001-1008.
[http://dx.doi.org/10.1056/NEJMcp013013] [PMID: 12324557]
[40]
Dindyal, S.; Kyriakides, C. A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. Recent Pat. Cardiovasc. Drug Discov., 2009, 4(1), 6-14.
[http://dx.doi.org/10.2174/157489009787260025] [PMID: 19149700]
[41]
Orange book: approved drug products with therapeutic equivalence evaluations. Available at: https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm(acceesed on: 24 March, 2021)
[42]
Cariski, A.T. Cilostazol: a novel treatment option in intermittent claudication. Int. J. Clin. Pract. Suppl., 2001, (119), 11-18.
[PMID: 11355274]
[43]
Bedenis, R.; Stewart, M.; Cleanthis, M.; Robless, P.; Mikhailidis, D.P.; Stansby, G. Cilostazol for intermittent claudication. Cochrane Database Syst. Rev., 2014, 2014(10), CD003748.
[http://dx.doi.org/10.1002/14651858.cd003748.pub4] [PMID: 25358850]
[44]
Yentes, J.M.; Huisinga, J.M.; Myers, S.A.; Pipinos, I.I.; Johanning, J.M.; Stergiou, N. Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain. J. Appl. Biomech., 2012, 28(2), 184-191.
[http://dx.doi.org/10.1123/jab.28.2.184] [PMID: 22723116]
[45]
Shinohara, Y.; Katayama, Y.; Uchiyama, S.; Yamaguchi, T.; Handa, S.; Matsuoka, K.; Ohashi, Y.; Tanahashi, N.; Yamamoto, H.; Genka, C.; Kitagawa, Y.; Kusuoka, H.; Nishimaru, K.; Tsushima, M.; Koretsune, Y.; Sawada, T.; Hamada, C. CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol., 2010, 9(10), 959-968.
[http://dx.doi.org/10.1016/S1474-4422(10)70198-8] [PMID: 20833591]
[46]
Kim, S.M.; Jung, J.M.; Kim, B.J.; Lee, J.S.; Kwon, S.U. Cilostazol mono and combination treatments in ischemic stroke: an updated systematic review and meta-analysis. Stroke, 2019, 50(12), 3503-3511.
[http://dx.doi.org/10.1161/STROKEAHA.119.026655] [PMID: 31607242]
[47]
Kwon, S.U.; Cho, Y.J.; Koo, J.S.; Bae, H.J.; Lee, Y.S.; Hong, K.S.; Lee, J.H.; Kim, J.S. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke, 2005, 36(4), 782-786.
[http://dx.doi.org/10.1161/01.STR.0000157667.06542.b7] [PMID: 15746463]
[48]
Nazli, Y.; Colak, N.; Namuslu, M.; Erdamar, H.; Haltas, H.; Alpay, M.F.; Nuri Aksoy, O.; Olgun Akkaya, I.; Cakir, O. Cilostazol attenuates spinal cord ischemia-reperfusion injury in rabbits. J. Cardiothorac. Vasc. Anesth., 2015, 29(2), 351-359.
[http://dx.doi.org/10.1053/j.jvca.2014.06.028] [PMID: 25440635]
[49]
Nakamura, T.; Houchi, H.; Minami, A.; Sakamoto, S.; Tsuchiya, K.; Niwa, Y.; Minakuchi, K.; Nakaya, Y. Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. Life Sci., 2001, 69(15), 1709-1715.
[http://dx.doi.org/10.1016/S0024-3205(01)01258-9] [PMID: 11665832]
[50]
Li, H.; Hong, D.H.; Son, Y.K.; Na, S.H.; Jung, W.K.; Bae, Y.M.; Seo, E.Y.; Kim, S.J.; Choi, I.W.; Park, W.S. Cilostazol induces vasodilation through the activation of Ca(2+)-activated K(+) channels in aortic smooth muscle. Vascul. Pharmacol., 2015, 70, 15-22.
[http://dx.doi.org/10.1016/j.vph.2015.01.002] [PMID: 25748552]
[51]
Liu, Y.; Shakur, Y.; Yoshitake, M.; Kambayashi Ji, J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc. Drug Rev., 2001, 19(4), 369-386.
[http://dx.doi.org/10.1111/j.1527-3466.2001.tb00076.x] [PMID: 11830753]
[52]
Liu, Y.; Fong, M.; Cone, J.; Wang, S.; Yoshitake, M.; Kambayashi, J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J. Cardiovasc. Pharmacol., 2000, 36(3), 351-360.
[http://dx.doi.org/10.1097/00005344-200009000-00011] [PMID: 10975593]
[53]
Shryock, J.C.; Belardinelli, L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol., 1997, 79(12A), 2-10.
[http://dx.doi.org/10.1016/S0002-9149(97)00256-7] [PMID: 9223356]
[54]
Lau, C.S.; McLaren, M.; Saniabadi, A.; Belch, J.J. Increased whole blood platelet aggregation in patients with Raynaud’s phenomenon with or without systemic sclerosis. Scand. J. Rheumatol., 1993, 22(3), 97-101.
[http://dx.doi.org/10.3109/03009749309099251] [PMID: 8316776]
[55]
Nomura, S.; Shouzu, A.; Omoto, S.; Hayakawa, T.; Kagawa, H.; Nishikawa, M.; Inada, M.; Fujimura, Y.; Ikeda, Y.; Fukuhara, S. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb. Haemost., 1998, 80(3), 388-392.
[PMID: 9759615]
[56]
Weintraub, W.S. The vascular effects of cilostazol. Can. J. Cardiol., 2006, 22(Suppl. B), 56B-60B.
[http://dx.doi.org/10.1016/S0828-282X(06)70987-4] [PMID: 16498513]
[57]
Cone, J.; Wang, S.; Tandon, N.; Fong, M.; Sun, B.; Sakurai, K.; Yoshitake, M.; Kambayashi, J.; Liu, Y. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J. Cardiovasc. Pharmacol., 1999, 34(4), 497-504.
[http://dx.doi.org/10.1097/00005344-199910000-00004] [PMID: 10511123]
[58]
Nietert, P.J.; Shaftman, S.R.; Silver, R.M.; Wolf, B.J.; Egan, B.M.; Hunt, K.J.; Smith, E.A. Raynaud phenomenon and mortality: 20+ years of follow-up of the Charleston Heart Study cohort. Clin. Epidemiol., 2015, 7, 161-168.
[http://dx.doi.org/10.2147/CLEP.S75482] [PMID: 25678814]
[59]
Rajagopalan, S.; Pfenninger, D.; Somers, E.; Kehrer, C.; Chakrabarti, A.; Mukherjee, D.; Brook, R.; Kaplan, M.J. Effects of cilostazol in patients with Raynaud’s syndrome. Am. J. Cardiol., 2003, 92(11), 1310-1315.
[http://dx.doi.org/10.1016/j.amjcard.2003.08.013] [PMID: 14636909]
[60]
Negrini, S.; Spanò, F.; Penza, E.; Rollando, D.; Indiveri, F.; Filaci, G.; Puppo, F. Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients. Clin. Exp. Med., 2016, 16(3), 407-412.
[http://dx.doi.org/10.1007/s10238-015-0370-5] [PMID: 26088182]
[61]
Zheng, H.; Yang, H.; Gong, D.; Mai, L.; Qiu, X.; Chen, L.; Su, X.; Wei, R.; Zeng, Z. Progress in the Mechanism and Clinical Application of Cilostazol. Curr. Top. Med. Chem., 2019, 19(31), 2919-2936.
[http://dx.doi.org/10.2174/1568026619666191122123855] [PMID: 31763974]
[62]
Pletal 50 mg tablets summary of product characteristics. Available at: https://www.medicines.org.uk/emc/product/164/smpc#companyDetails (acceesed on: 24 March, 2021)
[63]
Wigley, F.M. Treatment of Raynaud phenomenon: initial management, Available at: https://www.uptodate.com/contents/treatment-of-raynaud-phenomenon-initial-management (acceesed on: 24 March, 2021)

Rights & Permissions Print Cite
Article Metrics
19
1
© 2024 Bentham Science Publishers | Privacy Policy